HWP
UTHR icon

Highline Wealth Partners’s United Therapeutics UTHR Stock Holding History

Highline Wealth Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190K Hold
351
– – 0.04% 114
2026
Q1 		$208K Buy
351
+350
+35,000% +$174K 0.05% 79
2025
Q4 		$487 Hold
1
– – ﹤0.01% 981
2025
Q3 		$419 Hold
1
– – ﹤0.01% 1010
2025
Q2 		$287 Hold
1
– – ﹤0.01% 843
2025
Q1 		$308 Buy
+1
New +$343 ﹤0.01% 908

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Highline Wealth Partners's UTHR Position: Q2 2026 in Review

Highline Wealth Partners held its United Therapeutics (UTHR) position steady in Q2 2026 at 351 shares worth $190K. The position accounts for 0.04% of the portfolio, ranked #114.

Highline Wealth Partners first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. The position peaked at $208K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Highline Wealth Partners held 351 shares of United Therapeutics worth $190K as of Q2 2026.
  • Highline Wealth Partners left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.04% of Highline Wealth Partners's portfolio in Q2 2026, its #114 holding.
  • Highline Wealth Partners first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Highline Wealth Partners's United Therapeutics position peaked at $208K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.